Article
ESMO: Pfizer's Ibrance flop in early breast cancer shouldn't hurt metastatic sales, exec says
Rating:
0.0
Views:
70
Likes:
1
Library:
1
Pfizer talked up Ibrance's potential in early breast cancer for years before getting the bad news this May: The Pallas study, in stage 2 and stage 3 patients with HR-positive, HER2-negative disease, was a flop. But while the failure means Ibrance will miss that sales opportunity, it shouldn't hurt the drug's revenue in the metastatic setting, one exec says.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value